Effect Aflibercept on Ocular Perfusion

Status Completed

Clinical Trial Summary

Age-related macular degeneration (AMD) is the leading cause of irreversible visual impairment in Western Countries. It is a well-established fact that vascular endothelial growth factor (VEGF) plays a key part in the development of the neovascular (or exsudative) form of AMD. Today, VEGF-inhibition by means of injection of anti-VEGF agents into the vitreous cavity constitutes the gold standard of AMD therapy. In physiological conditions, VEGF acts as a vasodilator by activating endothelial nitric oxide synthase. As a consequence, VEGF inhibition should result in significant ocular vasoconstriction, which has in fact been demonstrated for bevacizumab and ranibizumab, two of the three available VEGF-inhibitors. The understanding and awareness of potentially harmful implications of the induced vasoconstriction on retinal and/or optic nerve head structure and function is sparse. This is especially delicate, as most patients with exsudative AMD require repeated injections on a monthly basis for many years. Aflibercept, the latest anti-VEGF agent approved for intravitreal use in 2011, offers a superior binding affinity for VEGF compared to the former two drugs. However, as of today, its effect on ocular circulation is unclear. With Laser Speckle Flowgraphy (LSFG), a commercially available, non-invasive and patient-friendly method for the evaluation of blood flow at the optic nerve head, the choroid and retina has arisen in recent years.

We aim to measure ocular perfusion with LSFG before and after 3 consecutive injections of aflibercept in unilateral neovascular age-related maculopathy.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Anti Vascular Endothelial Growth Factor
Macular Degeneration

Clinical Trial Details

NCT number	NCT03804099
Study type	Interventional
Source	Augenabteilung Allgemeines Krankenhaus Linz
Contact
Status	Completed
Phase	Phase 4
Start date	March 1, 2017
Completion date	May 18, 2018

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT06262737` - Single-center Study Measuring OSDI Dry Eye Score in Patients Undergoing an Anti-VEGF Induction Protocol
Completed	`NCT02540954` - Efficacy and Safety of Two Different Aflibercept Regimens in Subjects With Neovascular Age-related Macular Degeneration (nAMD)	Phase 3
Completed	`NCT00385333` - Metabolic Mapping to Measure Retinal Metabolism	Phase 2
Completed	`NCT02510794` - Study of the Efficacy and Safety of the Ranibizumab Port Delivery System for Sustained Delivery of Ranibizumab in Patients With Subfoveal Neovascular Age-Related Macular Degeneration	Phase 2
Completed	`NCT02181504` - A Study of Abicipar Pegol in Japanese Patients With Neovascular Age-related Macular Degeneration	Phase 2
Completed	`NCT02390245` - Philadelphia Telemedicine Glaucoma Detection and Follow-Up Study	N/A
Terminated	`NCT02228304` - Study of the Intravitreal Implantation of NT-503-3 Encapsulated Cell Technology (ECT) for the Treatment of Recurrent Choroidal Neovascularization (CNV) Secondary to Age-related Macular Degeneration (AMD)	Phase 1/Phase 2
Recruiting	`NCT01521065` - An Open-label Study to Evaluate the Clinical and Economic Benefits of I-Ray in Patients With Choroidal Neovascularization Secondary to Age-related Macular Degeneration	Phase 2
Completed	`NCT01204541` - A Single-Center Pilot Study to Assess Macular Function	N/A
Completed	`NCT00769392` - Pilot Study: A Randomized Trial Of Anesthetic Agents For Intravitreal Injection	N/A
Completed	`NCT00533520` - Evaluation of Dosing Interval of Higher Doses of Ranibizumab	Phase 4
Withdrawn	`NCT00538538` - Subretinal Lucentis for Hemorrhagic Age-related Macular Degeneration (AMD)	Phase 1
Completed	`NCT00536016` - A Phase 1 Safety Study of Single and Repeated Doses of JSM6427 (Intravitreal Injection) to Treat AMD	Phase 1
Terminated	`NCT00403442` - Bevacizumab in Combination With Verteporfin Reduced and Standard Fluence in the Treatment of Hemorrhaged Lesions in Neovascular AMD	Phase 1
Recruiting	`NCT00157976` - Double-Masked Study of Photrex (Rostaporfin) Photodynamic Therapy in the Treatment of Age-Related Macular Degeneration	Phase 3
Completed	`NCT00242580` - A Safety and Efficacy Study Comparing the Combination Treatments of Verteporfin Therapy Plus One of Two Different Doses of Intravitreal Triamcinolone Acetonide and the Verteporfin Therapy Plus Intravitreal Pegaptanib	Phase 3
Completed	`NCT00211458` - Treatment of Age-Related Macular Degeneration With Anecortave Acetate	Phase 2
Completed	`NCT00239928` - Clinical Study Of Pegaptanib Sodium (EYE001) For Wet-Type Age-Related Macular Degeneration	Phase 2
Completed	`NCT00095433` - Extension Study of rhuFab V2 in Subjects With Neovascular Age-Related Macular Degeneration (AMD)	Phase 3
Completed	`NCT00006202` - Lutein for Age-Related Macular Degeneration	Phase 2